The Effectiveness of Fu’s Subcutaneous Needling for Residual Pain After Percutaneous Vertebral Augmentation in Osteoporotic Vertebral Compression Fractures: A Randomized Clinical Trial Protocol [Letter]
Journal of Pain Research · 2026-04 · Volume 19 · 1-2
DOI: 10.2147/jpr.s611825 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Pain Research, 2026-04. Verfasst von Ling-Qian Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
We read with great interest the study protocol by Wang et al 1 This study has the potential to provide high-level evidence for the use of Fu’s Subcutaneous Needling (FSN) in managing persistent pain after osteoporotic vertebral compression fractures (OVCFs), and may serve as a feasible non-pharmacological alternative for chronic postoperative pain management. However, several issues merit further clarification to enhance the rigor and impact of the study. First, there is an internal inconsistency in the definition of the primary outcome. The abstract identifies the Oswestry Disability Index (ODI) as the primary endpoint, whereas the main text designates the Visual Analog Scale (VAS) as the primary outcome, and the sample size calculation is based on ODI. This inconsistency undermines the coherence among the study hypothesis, sample size estimation, and statistical analysis. According to the SPIRIT-Outcomes extension, 2 primary outcomes should be pre-specified, clearly defined, and consistently reported to minimize selective reporting bias. We recommend that the authors define a single primary outcome and ensure consistency across the abstract, trial registration, methods, and statistical analysis sections. In addition, incorporating the minimal clinically important difference (MCID) into both sample size estimation and result interpretation would better align the study with contemporary high-quality RCT standards focusing on clinically meaningful patient benefit. Second, the follow-up duration of 30 days after treatment appears insufficient. In patients with residual pain following OVCF surgery, early pain relief
Autor:innen und Institutionen
- The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, People's Republic of China.
ORCID-Profile: Rui-Jie Ma
Zitieren
APA
Chen, L. Q., & Ma, R. J. (2026). The Effectiveness of Fu’s Subcutaneous Needling for Residual Pain After Percutaneous Vertebral Augmentation in Osteoporotic Vertebral Compression Fractures: A Randomized Clinical Trial Protocol [Letter]. Journal of Pain Research, Volume 19, 1-2. https://doi.org/10.2147/jpr.s611825
Vancouver
Chen LQ, Ma RJ. The Effectiveness of Fu’s Subcutaneous Needling for Residual Pain After Percutaneous Vertebral Augmentation in Osteoporotic Vertebral Compression Fractures: A Randomized Clinical Trial Protocol [Letter]. Journal of Pain Research. 2026;Volume 19:1-2. doi:10.2147/jpr.s611825
BibTeX
@article{Chen2026,
author = {Chen, Ling-Qian and Ma, Rui-Jie},
title = {The Effectiveness of Fu’s Subcutaneous Needling for Residual Pain After Percutaneous Vertebral Augmentation in Osteoporotic Vertebral Compression Fractures: A Randomized Clinical Trial Protocol [Letter]},
journal = {Journal of Pain Research},
year = {2026},
volume = {Volume 19},
pages = {1--2},
doi = {10.2147/jpr.s611825}
}
EUVIMED